Cytotoxicity and anti-Sporothrix brasiliensis activity of the Origanum majorana Linn. oil

Abstract

The study aimed to evaluate the anti-Sporothrix sp. activity of the essential oil of Origanum majorana Linn. (marjoram), its chemical analysis, and its cytotoxic activity. A total of 18 fungal isolates of Sporothrix brasiliensis (n: 17) from humans, dogs and cats, and a standard strain of Sporothrix schenckii (n: 1) were tested using the broth microdilution technique (Clinical and Laboratory Standard Institute - CLSI M27-A3) and the results were expressed in minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC). The MIC₅₀ and MIC₉₀ of itraconazole against S. brasiliensis were 2 µg/mL and 8 µg/mL, respectively, and the MFC₅₀ and MFC₉₀ were 2 µg/mL and >16 µg/mL, respectively, with three S. brasiliensis isolates resistant to antifungal. S. schenckii was sensitive at MIC of 1 µg/mL and MFC of 8 µg/mL. For the oil of O. majorana L., all isolates were susceptible to MIC of ≤2.25-9 mg/mL and MFC of ≤2.25-18 mg/mL. The MIC₅₀ and MIC₉₀ were ≤2.25 mg/mL and 4.5 mg/mL, respectively, and the MFC_50/90 values were twice more than the MIC. Twenty-two compounds were identified by gas chromatography with a flame ionization detector (CG-FID) and 1,8-cineole and 4-terpineol were the majority. Through the colorimetric (MTT) assay, the toxicity was observed in 70-80% of VERO cells between 0.078 and 5 mg/mL. For the first time, the study demonstrated the satisfactory in vitro anti-Sporothrix sp. activity of marjoram oil and further studies are needed to ensure its safe and effective use.

Keywords: Sporotrichosis; Sporothrix schenckii complex; Antifungal resistance; Marjoram; Lamiaceae

Introduction

Sporotrichosis is a zoonotic mycosis caused by the fungus of Sporothrix schenckii complex, such as S. schenckii var. schenckii, S. schenckii var. luriei, S. brasiliensis, S. globosa, S. mexicana and S. albicans.^1,2 This disease has a worldwide occurrence, mainly in countries of America, such as Brazil, Mexico, Colombia, Uruguay and Peru, and also in South Africa, India, Japan.^3,4 The infection is acquired through the traumatic inoculation by conidial and can be transmitted through scratch and bite of sick cats.^5,6S. brasiliensis is considered the most virulent among the complex species and with a high prevalence in Brazil, being geographically restricted to this country.^7,8

Limited lesions to skin and subcutaneous tissue may arise in the host and may have lymphatic involvement with systemic clinical signs.⁹ The treatment of choice is performed with the antifungal itraconazole^10-12; however, the appearance of resistant strains of Sporothrix sp. has been observed because of the indiscriminate use of several antifungals in therapies.^2,13,14

This problem has stimulated the search for new effective chemical compounds, such as those in medicinal plants, but only approximately 30% of antimicrobial medications in the market are derived from natural products and the resources for elaborate drugs from plants are poorly explored.¹⁵ In folk medicine, marjoram (Origanum majorana Linn., synonymous of Majorana hortensis Linn.) is used to treat asthma, indigestion, cramps, headache, dizziness, depression, and rheumatism, and it has diuretic activity.^16,17 This plant has a strong antioxidant activity attributed to its high content of flavonoids and phenolic acids, which are used for food preservation.¹⁸ Essential oil of O. majorana L. has shown antimicrobial properties, such as antiviral, antibacterial and antifungal,^18-22 among others.

The pathogenic fungi of human and veterinary medical interest that were sensitive to the essential oil of O. majorana L. are Candida sp., Aspergillus sp., Trichophyton sp., Microsporum sp., Malassezia sp. and Trichosporon sp.^21,23,24 These results in vitro show its promising activity in fungal diseases, including those with zoonotic potential. In sporotrichosis, no studies with O. majorana L. have been done, which encouraged the development of this work. This study aimed to evaluate the in vitro efficacy of O. majorana L. essential oil against clinical isolates of S. schenckii complex and to analyze its chemical constituents and cytotoxic activity in mammalian cells.

Materials and methods

Plant material

The essential oil of O. majorana Linn., originating from Egypt, was obtained from Ferquima ^® Indústria e Comércio Ltda. (Vargem Grande Paulista, São Paulo, SP, Brazil), for which quality parameters are described in an accompanying technical report (appearance, color, purity, odor, density - 20 °C, refraction index - 20 °C).

Chemical analysis

Chemical analysis was performed using high-resolution gas chromatography with a flame ionization detector (CG-FID) by HP 7820A (Agilent^®) equipped with an HP-5 column (30 m × 0.32 mm × 0.25 mm) at an initial temperature of 70 °C with the addition of 3 °C/min up to 240 °C. The injector temperature was 250 °C, and that of the FID detector was 260 °C. The speed of the drag of hydrogen gas was 3 mL/min, and that of the split was 1:30. The solution of essential oil was diluted with 1% chloroform and injected into the chromatograph at a volume of 1 µL. Data were acquired through the EZChrom Elite Compact^® program (Agilent).

Cytotoxicity assay

The cytotoxic effects of O. majorana L. were estimated using the colorimetric MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay that measures the reduction of the MTT dye to an insoluble and colored formazan. The technique was executed as previously described,²⁵ and tested in mammalian cells of VERO type, which were grown in RPMI-1640 (Roswell Park Memorial Institute medium, Sigma, Steinheim, Germany) supplemented with l-glutamine, without sodium bicarbonate (pH 7.2) and added of penicillin-streptomycin and fungizone in a humidified atmosphere of 5% CO₂ at 37 °C. Trypsin was added on to the cell monolayer and the cells were resuspended in RPMI-1640, resulting in a suspension with approximately 2 × 10⁵ cells/mL. Aliquots of this cells suspension were placed in individual wells in 96-well microplate except first well as blank. Cells were incubated in RPMI-1640 medium supplemented with 10% fetal calf serum at CO₂ 5%, 37 °C by 24 h.

Subsequently, 100 µL of the oil in seven successive concentrations on a logarithmic scale was added in the microplates. Concentrations of 5-0.078 mg/mL of the essential oil diluted in RPMI-1640 were tested in triplicate for 48 h at 37 °C in a humidified atmosphere of 5% CO₂ and for control RPMI-1640 only was used. Then, 50 µL MTT solution (2.5 mg/mL) was added in each well and incubated for 2 h and 30 min at 37 °C and 5% CO₂. After removal of MTT solution, 50 µL of dimethylsulfoxide (DMSO) was added to each well to dissolve the formazan crystals, and gentle shaking for 5 min. The spectrophotometric absorbance of the samples was measured using a microplate reader at wavelength of 540 nm. The appearance of cells was monitored by inverted microscope and the results were expressed as an inhibition percentage relative to the control cells, which was considered 100%.

Fungal isolates

For the antifungal susceptibility test, seventeen clinical isolates of S. brasiliensis derived from humans (n: 3), dogs (n: 6), and cats (n: 8) with sporotrichosis were used along with a standard strain of S. schenckii (IOC 1226) from human case (n: 1), totaling eighteen tested isolates. The fungal isolates were stored in mycology collection of the Centro de Diagnóstico e Pesquisa em Micologia Veterinária (Universidade Federal de Pelotas - UFPEL - Pelotas, RS, Brazil) and cooled in an average temperature of 4 °C. The mycology identification of S. brasiliensis was analyzed using the polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP), proposed by Rodrigues et al.²⁶

Antifungal activity

The antifungal susceptibility tests were performed using the broth microdilution technique, according to the M27-A3 guidelines of the Clinical and Laboratory Standards Institute,²⁷ adapted for the use of essential oil. Subcultures in Brain-Heart-Infusion agar (BHI, Acumedia, Lansing, MI, USA) at 35 °C for 48 h were performed. A portion of each fungal colony was transferred to individual tubes containing sterile saline solution and adjusted according to the scale of 1.0 McFarland and in the ultraviolet (UV)-visible spectrophotometer (Spectrum Instruments Co., Shanghai, China) in transmittance at 530 nm and at an absorbance of 80-82%. The suspensions were adjusted in saline solution (1:100) and, then, in RPMI-1640 with 3-morpholinopropane-1-sulfonic acid - MOPS - (1:20) in order to obtain the final inoculum concentration of 5 × 10⁴ CFU/mL.

In a microplate with ninety-six wells containing 100 µL of RPMI-1640 with MOPS in each well, 100 µL of essential oil of O. majorana L. containing 1% Tween 80 was added to the column corresponding to a higher concentration of the product, and serial dilutions were performed. The oil plant was tested in the concentrations of 72-2.25 mg/mL. Then, 100 µL of the inoculum was added to all wells except in the negative control, where 100 µL of the marjoram essential oil was added. Itraconazole was used as the positive control and was prepared in dimethyl sulfoxide and diluted in RPMI-1640 medium with MOPS in order to obtain the final concentrations of 16-0.0313 µg/mL. The microplates were incubated on a rotatory shaker (Certomat^® BS-1, B. Sartorius, Göttingen, Germany) at 35 °C for 72 h, and the minimal inhibitory concentration (MIC) was visually compared with that of the negative control and was defined as the lowest concentration of the tested product inhibiting the visible growth of the fungus (100% inhibition).

For the minimal fungicidal concentration (MFC), 10 µL of aliquots of the wells with no fungal growth was transferred to Petri dishes containing Sabouraud dextrose agar (Acumedia, Lansing, MI, USA) and incubated at 35 °C for 72 h to visualize fungal growth. MFC was determined to be the lowest concentration able to eliminate fungal growth. All experiments were performed in duplicate.

Statistical analysis

The analysis of variance and comparison of geometric means were performed according to Tukey test using the statistical software BioEstat^®, 5.3 version, and value p < 0.05 was considered significant.

Results

Antifungal activity

According to the results of the anti-Sporothrix sp. activity of the essential oil of O. majorana L. and itraconazole (Table 1), no significant difference existed between the results in the MIC values; however, the MFC values differed statistically (p = 0.05) between itraconazole and essential oil, in which O. majorana L. presented better results. All tested isolates were susceptible to the essential oil of marjoram with fungistatic activity being observed at concentrations of ≤2.25-9 mg/mL, while fungicidal activity occurred between ≤2.25 and 18 mg/mL. The concentrations of the oil up to 9 mg/mL showed antifungal activity against all S. brasiliensis, the MIC₅₀ and MIC₉₀ being observed at the concentrations ≤2.25 mg/mL and 4.5 mg/mL, respectively. At the minimal concentration tested of the oil, 66.7% (2/3) of the humans isolates, 83.3% (5/6) of the isolates from dogs and 50% (4/8) from cats were sensitive (MIC ≤2.25 mg/mL), as well as the standard strain of S. schenckii. In the fungicidal activity, the MFC₅₀ and MFC₉₀ values of overall S. brasiliensis were 4.5 mg/mL and 9 mg/mL, respectively, and were twice the MIC_50/90 values, whereas the standard strain was more sensitive (MFC ≤2.25 mg/mL). In relation to the itraconazole, all isolates were sensitive to the fungistatic activity between the MIC values ≤0.03 and 16 µg/mL, which MIC₅₀ was 1 µg/mL and MIC₉₀ was 16 µg/mL. However, the fungicidal activity was observed between ≤0.03 and >16 µg/mL, where MFC₅₀ was 2 µg/mL, but the MFC₉₀ was >16 µg/mL, indicating that 17.6% (3/17) of the S. brasiliensis were resistant to the maximal concentration tested of this antifungal.

Table 1
Minimal inhibitory concentration (MIC) and minimal fungicidal concentration (MFC) of the Origanum majorana Linn. essential oil and itraconazole against Sporothrix brasiliensis and Sporothrix schenckii.

Origin of the isolates of Sporothrix schenckii complex	Origanum majorana L. (mg/mL)								Itraconazole (µg/mL)
	MIC				MFC				MIC					MFC
	Range	50%	90%		Range	50%	90%		Range	50%		90%		Range	50%	90%
Sporothrix brasiliensis
Humans (n: 3)	≤2.25–4.5	–	–		≤2.25–4.5	–	–		≤0.03–0.5	–		–		≤0.03 to 2	–	–
Dogs (n: 6)	≤2.25–4.5	≤2.25	≤2.25		≤2.25–18	4.5	9		0.5–8	1		2		1 to >16	2	16
Cats (n: 8)	≤2.25–9	≤2.25	4.5		≤2.25–9	4.5	9		≤0.03–16	2		16		0.25 to >16	2	>16
Overall (n: 17)	≤2.25–9	≤2.25	4.5		≤2.25–18	4.5	9		≤0.03–16	2		8		≤0.03 to >16	2	>16
Sporothrix schenckii
IOC 1226 (n: 1)	≤2.25	–	–		≤2.25	–	–		1	–		–		8	–	–
Overall (n: 18)	≤2.25–9	≤2.25	4.5		≤2.25–18	4.5	9		≤0.03–16	1		16		≤0.03 to >16	2	>16

• 50%, MIC/MFC at which 50% of isolates were inhibited/eliminated; 90%, MIC/MFC at which 90% of isolates were inhibited/eliminated.

Chemical composition

Chemical analysis found twenty-two compounds, and 1,8-cineole was the majority component, followed by 4-terpineol, γ-terpinene, p-cymene, sabinene, and others (Table 2).

Table 2
Chemical constituents identified in the essential oil of Origanum majorana L. and respective concentrations through high resolution gas chromatography in a flame ionization detector (CG-FID).

Constituents	Retention rate	Area	Concentration (%)
α-Thujene	932	281,814	1.1
α-Pinene	932	494,138	2.0
Camphene	941	96,074	0.4
Sabinene	946	1,669,329	6.7
β-Pinene	975	470,225	1.9
Myrcene	984	408,894	1.6
α-Phellandrene	1003	226,808	0.9
α-Terpinene	1015	1,152,102	4.6
p-Cymene	1019	1,755,163	7.0
Limonene	1023	1,316,921	5.3
1,8-Cineole	1027	5,222,929	20.9
β-Ocimene	1056	34,661	0.1
γ-Terpinene	1089	2,130,943	8.5
Trans sabinene hydrate	1094	564,967	2.3
Linalool	1099	1,096,294	4.4
Camphor	1142	48,346	0.2
Terpinen-4-ol	1175	5,100,062	20.4
α-Terpineol	1188	1,162,894	4.7
Linalyl acetate	1261	438,735	1.8
Bornila acetate	1285	212,333	0.8
β-Caryophyllene	1421	546,553	2.2
Humulene	1453	41,993	0.2
Others		517,426	2.1

Cytotoxic effects

In the observed values of MIC₅₀ and MIC₉₀ for total isolates, the cytotoxicity of O. majorana L. occurred between 77.5% and 78.91%. The toxicity activity in mammalian cells was directly proportional to tested concentrations and decreased to 73.45% at a concentration of 0.078 mg/mL (Fig. 1).

Fig. 1
Cytotoxic percentage (%) of the essential oil of Origanum majorana L. in VERO cells tested through MTT assay in the concentration of 0.078-5 mg/mL.

Discussion

Antifungal activity

The drug of choice in the treatment of sporotrichosis was effective against several S. brasiliensis, being similar to the findings of Marimon et al.,² that showed in vitro activity between 0.5 and 2 µg/mL against twenty-three isolates of S. brasiliensis, with MIC₅₀ and MIC₉₀ of 0.5 µg/mL and 1 µg/mL, respectively. In our work, the MIC₅₀ and MIC₉₀ found were 2 µg/mL and 8 µg/mL, demonstrating that the fungal isolates of S. brasiliensis originating from humans and animals in the south of Brazil were twice more resistant.

In isolates from humans, no resistance was observed, and according Kauffman et al.²⁸ and Yamada et al.,²⁹ the resistance was lower compared to that of animals, mainly cats, due to greater care during human therapy in relation to their own health. In relation to feline sporotrichosis, it is known to have a high incidence in the Southeast and Southern regions of Brazil.^8,11,30,31 MIC₅₀ of itraconazole against S. brasiliensis isolated from cats were 2 µg/mL, but the MIC₉₀ was 16 µg/mL, demonstrating its lower susceptibility to antifungal. In the overall S. brasiliensis tested, one clinical isolate from a dog and two isolates from cats were resistant to the fungicidal activity (MFC >16 µg/mL).

This observation may be a reflection of previous factors that favor the emergence of antifungal resistance. It is noticed that the antifungal administered in animals may not always be the same used in humans and its efficacy may be affected due to pharmacokinetics parameters and kind of formulation, among others,³² and a difference in the pharmaceutical technology between human and veterinary drugs may occur,³³ which may influence the therapeutic antifungal response. Besides, the irregularities in veterinary therapeutic management by animal owners are common due to the difficulties in the oral administration and high cost of antifungals and this often culminates in the abandonment of therapy, particularly when there is improvement of skin lesions.³⁴

The resistance of Sporothrix spp. to itraconazole has been evidenced by Rodrigues et al.,¹⁴ and this problem reflects in an alert because sporotrichosis is important in the public health. Interestingly, the same resistant isolates were susceptible to essential oil in concentrations equal to or less than 9 mg/mL, thus suggesting that this plant can be used for further studies in the treatment of sporotrichosis. In accordance with our study, Souza et al.²³ showed the promising activity of the commercial essential oil of O. majorana L. at 160 µL/mL against pathogenic fungi, including in strains of Candida albicans, C. tropicalis, Cryptococcus neoformans, T. mentagrophytes, M. gypseum and A. flavus, which were resistant to conventional antifungal, as amphotericin B, 5-fluorocytosine and fluconazole. This observation reflects in the promising use of this essential oil in antifungal therapies.

No valid criteria exist for the minimal antifungal concentrations in vitro tests with plant extracts,³⁵ but O. majorana L. oil showed satisfactory activity with MIC₅₀ and MIC₉₀ of ≤2.25 mg/mL and 4.5 mg/mL, respectively, including in resistant isolates to itraconazole (n: 3), that were sensitive to the plant at MIC of ≤2.25 mg/mL for one isolate from dog and one from cat, and at MIC of 9 mg/mL for one isolate from cat. No studies were found on the activity of O. majorana L. in S. schenckii complex, and for the first time, the in vitro sensibility of S. brasiliensis to this plant was studied.

Similar to our study, the resistance of S. schenckii and S. brasiliensis to itraconazole also was reported as sensitive to plant extracts from the Pterocaulon genus³⁵ and Camellia sinensis L.,³⁶ respectively, indicating the promising use of the several plants in the sporotrichosis. Furthermore, resistance of bacteria and yeasts to antimicrobial drugs was sensitive to the essential oils of Rosmarinus officinalis L.³⁷ and Origanum vulgare L.^38,39 showing that, as found in this study with O. majorana L., other medicinal plants also are potential candidates as new antimicrobial agents. Given this fact, it is necessary to explore the studies for their promising use in the treatment of sporotrichosis.

Chemical composition

The chemical compounds were similar to those scientifically described.^18,21,24,40 However, our data differed from the findings by Marino et al.,⁴¹ in which thymol and carvacrol were prevalent. The presence of phenolic compounds in plants is highly correlated to antimicrobial properties,^40,42 but the identified compounds were predominated by terpenoids, which were related to antimicrobial activity when tested alone.⁴³ The plant causes an increase in the permeability of the cytoplasmatic fungal membrane, destroying the physical structure.⁴⁴ However, Souza et al.²³ suggested that the essential oil of O. majorana L. acts as an inhibitor of the microorganism's cell wall, although other mechanisms for expressing their anti-Sporothrix sp. activity may be involved.

Cytotoxic effects

O. majorana L. oil presented a cytotoxicity between 73.45% and 78.91% in the tested concentrations, which were high, but the gradual reduction of the cytotoxicity to the lower tested concentration should be noted. In overall isolates, 66.67% (12/18) of tested Sporothrix spp. were sensitive to the MIC ≤2.25 mg/mL, indicating that the lower concentrations may present inhibitory activity with lower cytotoxicity. Although the maximal non-toxic concentration of O. majorana L. essential oil in VERO cells was 3.2 µg/mL,²² this value was four times lower than the minimal tested concentration. However, it is noticed that the use of the O. majorana L. oil against sporotrichosis need to be studied at its effective antifungal concentrations and, also, our study was performed in vitro.

According to Nogueira and Andrade,⁴⁵ the mammalian cells in the MTT test are more susceptible in comparison to the in vivo test due to the direct exposure of the product, whereas to the in vivo the product is influenced by the route of administration under consideration, that can suffer internal actions by oral administration, as well as influence by topical absorption, and may present lower toxic potential. The dose and frequency of administration can influence the degree of toxicity of medicinal plants,⁴⁶ and low doses can cause an allergic reaction in sensitive patients as well as skin irritations.^47,48 Studies on the toxic effects of this plant in vivo should be conducted in order to evaluate the influence of its dose and the route of administration in patients with sporotrichosis.

Conclusion

The in vitro activity of O. majorana L. essential oil against S. brasiliensis and S. schenckii, including in resistant isolates to itraconazole, encourages greater studies on antifungal potential of this promising plant, that had 1,8-cineole as majority compound among chemical constituents identified. However, the cytotoxic activity of O. majorana L. oil was observed between 70% and 80% of mammalian cells in all concentrations tested. Further studies are needed to ensure its safe and effective use.

Acknowledgments

We thank Zoilo Pires de Camargo (Universidade Federal de São Paulo, UNIFESP, São Paulo, SP, Brazil) for the biomolecular analysis of the clinical isolates and CNPq, CAPES and FAPERGS for financial support and providing scholarships.

References

• ¹ Marimon R, Cano J, Gené J, Sutton DA, Kawasaki M, Guarro J. Sporothrix brasiliensis, S. globosa and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol 2007;45:3198-3206.
• ² Marimon R, Serena C, Géne J, Cano J, Guarro J. In vitro antifungal susceptibilities of five species of Sporothrix schenckii Antimicrob Agents Chemother 2008;52:732-734.
• ³ Silva MBT, Costa MMM, Torres CCS, et al. Urban sporotrichosis: a neglected epidemic in Rio de Janeiro, Brazil. Cad Saúde Pública 2012;28(10):1867-1880.
• ⁴ Carrada-Bravo T, Olvera-Macías MI. New observations on the ecology and epidemiology of Sporothrix schenckii and sporotrichosis. Rev Latinoam Patol Clin 2013;60:5-24.
• ⁵ Xavier MO, Nobre MO, Sampaio DP, et al. Esporotricose felina com envolvimento humano na cidade de Pelotas, RS, Brasil. Ciênc Rural 2004;34(6):1961-1963.
• ⁶ Cruz LCH. Complexo Sporothrix schenckii Revisão de parte de literatura e considerações sobre diagnóstico e a epidemiologia. Vet Zootec 2011;20:8-28.
• ⁷ Rodrigues AM, de Melo TM, de Hoog GS, et al. Phylogenetic analysis reveals a high prevalence of Sporothrix brasiliensis in feline sporotrichosis outbreaks. PLoS Negl Trop Dis 2013;7:e2281.
• ⁸ Montenegro H, Rodrigues AM, Dias MAG, da Silva EA, Bernardi F, de Camargo ZP. Feline sporotrichosis due to Sporothrix brasiliensis: an emerging animal infection in São Paulo, Brazil. BMC Vet Res 2014;10:269.
• ⁹ Larsson CE. Esporotricose. Braz J Vet Res Anim Sci 2011;48(3):250-259.
• ¹⁰ Honse CO, Rodrigues AM, Gremião IDF, Pereira AS, Schubach TM. Use of local hyperthermia to treat sporotrichosis in a cat. Vet Rec 2010;166(7):208-209.
• ¹¹ Madrid IM, Mattei AS, Martins AF, Nobre MO, Meireles MCA. Feline sporotrichosis in the southern region of Rio Grande do Sul, Brazil: clinical, zoonotic and therapeutic aspects. Zoonoses Public Health 2010;57(2):151-154.
• ¹² Pereira SA, Passos SRL, Silva JN, et al. Response to azolic antifungal agents for treating feline sporotrichosis. Vet Rec 2010;166:290-294.
• ¹³ Gutierrez-Galhardo MC, Zancopé-Oliveira RM, Monzón A, Rodriguez-Tudela JL, Cuenca-Estrella M. Antifungal susceptibility profile in vitro of Sporothrix schenckii in two growth phases and by two methods: microdilution and E-test. Mycoses 2010;53(3):227-231.
• ¹⁴ Rodrigues AM, de Hoog GS, Pires DC, et al. Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis. BMC Infect Dis 2014;14:219.
• ¹⁵ Chattopadhyay D, Chawla-Sarkar M, Chatterjee T, et al. Recent advancements for the evaluation of anti-viral activities of natural products. N Biotechnol 2009;25(5):348-365.
• ¹⁶ Van Den Broucke CO, Lemli JÁ. Antispasmodic activity of Origanum compactum Planta Med 1980;38:317-331.
• ¹⁷ Jun WJ, Han BK, Yu KW, et al. Antioxidant effects of Origanum majorana L. on superoxide anion radicals. Food Chem 2001;75:439-444.
• ¹⁸ Vági E, Simándi B, Suhajda Á, Héthelyi É. Essential oil composition and antimicrobial activity of Origanum majorana L. extracts obtained with ethyl alcohol and supercritical carbon dioxide. Food Res Int 2005;38:51-57.
• ¹⁹ Daferera DJ, Ziogas BN, Polissiou MG. GC-MS analysis of essential oils from some Greek aromatic plants and their fungitoxicity on Penicillium digitatum J Agric Food Chem 2000;48:2576-2581.
• ²⁰ Nostro A, Blanco AR, Cannatelli MA, et al. Susceptibility of methicillin-resistant Staphylococci to oregano essential oil, carvacrol and thymol. FEMS Microbiol Lett 2004;230:191-195.
• ²¹ Busatta C, Vidal RS, Popiolski AS, et al. Application of Origanum majorana L. essential oil as an antimicrobial agent in sausage. Food Microbiol 2008;25:207-211.
• ²² Erdoğan IO, Ozcelik B, Kartal M, Kan Y. Antimicrobial and antiviral effects of essential oils from selected Umbelliferae and Labiatae plants and individual essential oil components. Turk J Biol 2012;36:239-246.
• ²³ Souza NAB, Lima EO, Guedes DN, Pereira FO, Souza EL, Sousa FB. Efficacy of Origanum essential oils for inhibition of potentially pathogenic fungi. Braz J Pharm Sci 2010;46(3):499-508.
• ²⁴ Santin R (Thesis) Potencial antifúngico e toxicidade de óleos essenciais da família Lamiaceae Porto Alegre, RS, Brasil: Faculdade de Veterinária, UFRGS; 2013, 104 p.
• ²⁵ Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65(1-2):55-63.
• ²⁶ Rodrigues AM, de Hoog GS, Camargo ZP. Genotyping species of the Sporothrix schenckii complex by PCR-RFLP of calmodulin. Diagn Microbiol Infect Dis 2014;78:383-387.
• ²⁷ CLSI – Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. M27-A3 Guideline. Approved Standard 3rd ed; 2008.
• ²⁸ Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007;45:1255-1265.
• ²⁹ Yamada K, Zaitz C, Framil VMS, Muramatu LH. Cutaneous sporotrichosis treatment with potassium iodide. A 24 year experience in São Paulo State, Brazil. Rev Inst Med Trop São Paulo 2007;53(2):89-93.
• ³⁰ Schubach TM, Schubach A, Okamoto T, et al. Evaluation of an epidemic of sporotrichosis in cats: 347 cases (1998-2001). J Am Vet Med Assoc 2004;224:1623-1629.
• ³¹ Madrid IM, Mattei AS, Fernandes CG, Nobre MO, Meireles MCA. Epidemiological findings and laboratory evaluation of sporotrichosis: a description of 103 cases in cats and dogs in southern Brazil. Mycopathologia 2012;173(4):265-273.
• ³² Mawby DI, Whittemore JC, Genger S, Papich MG. Bioequivalence of orally administered generic, compounded, and innovator-formulated itraconazole in healthy dogs. J Vet Intern Med 2014;28:72-77.
• ³³ Cunningham F, Elliott J, Lees P. Comparative and Veterinary Pharmacology Berlin, Germany: Springer Science & Business Media; 2010.
• ³⁴ Chaves AR, Campos MP, Barros MBL, et al. Treatment abandonment in feline sporotrichosis - study of 147 cases. Zoonoses Public Health 2013;60:149-153.
• ³⁵ Stopiglia CDO, Vianna DR, Meirelles GC, Teixeira H, Von Poser GL, Scroferneker ML. Antifungal activity of Pterocaulon species (Asteraceae) against Sporothrix schenckii J Mycol Med 2011;21(3):169-172.
• ³⁶ Waller SB, Madrid IM, Serra EF, Gomes AR, Cleff MB, Faria RO. In vitro susceptibility of the Sporothrix brasiliensis to aqueous extracts of green-tea (Camellia sinensis L. Kuntze). Acta Vet Bras 2015;9(4):342-347.
• ³⁷ Luqman S, Dwivedi GR, Darokar MP, Kalra A, Khanuja SPS. Potential of Rosemary oil to be used in drug-resistant infections. Altern Ther Health Med 2007;13(5):54-59.
• ³⁸ Cleff MB, Meinerz ARM, Schuch LFD, Rodrigues MRA, Meireles MCA, Mello JRB. In vitro activity of the essential oil of Origanum vulgare against Sporothrix schenckii Arq Bras Med Vet Zootec 2008;60(2):513-516.
• ³⁹ Maida I, Lo Nostro A, Pesavento G, et al. Exploring the anti-Burkholderia cepacia complex activity of essential oils: a preliminary analysis. Evid Based Complement Altern Med 2014. Article ID 573518, 10 p..
• ⁴⁰ Sfeir J, Lefrançois C, Baudoux D, Derbré S, Licznar P. In vitro antibacterial activity of essential oils against Streptococcus pyogenes Evid Based Complement Altern Med 2013. Article ID 269161, 9 p.
• ⁴¹ Marino M, Bersani C, Comi G. Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae. Int J Food Microbiol 2001;67:187-195.
• ⁴² Ferrara LK, Montesanto D, Chiantese C. Origanum marjoran L. in medicine and foods. Ingred Aliment 2003;2:23-25.
• ⁴³ Kurekci C, Padmanabha J, Bishop-Hurley SL, Hassan E, Al-Jassim RA, McSweeney CS. Antimicrobial activity of essential oils and five terpenoid compounds against Campylobacter jejuni in pure and mixed culture experiments. Int J Food Microbiol 2013;166(3):450-457.
• ⁴⁴ Ultee A, Smid EJ. Influence of carvacrol on growth and toxin production by Bacillus cereus Int J Food Microbiol 2001;64:373-378.
• ⁴⁵ Nogueira RMB, Andrade SF. Manual de Toxicologia Veterinária Brasil: Ed. I. Roca; 2011.
• ⁴⁶ Veiga VF, Pinto AC, Maciel MAM. Plantas Medicinais: Cura Segura?. Quím Nova 2005;28(3):519-528.
• ⁴⁷ Baričcevič D, Bartol T. The biological/pharmacological activity of the oregano genus. In: Kintzios S, ed. Oregano: The Genera Origanum and Lippia, Medicinal and Aromatic Plants – Industrial Profiles London, England: Taylor & Francis; 2002:177–214.
• ⁴⁸ Lorenzi H, Matos FJ. Plantas Medicinais no Brasil: Nativas e Exóticas Cultivadas Nova Odessa, SP: Editora Instituto Plantarum; 2006.

Publication Dates

• Publication in this collection
  Oct-Dec 2016

History

• Received
  31 July 2015
• Accepted
  6 Mar 2016